HIV replication machinery

The HIV replication machinery refers to the collective ensemble of virally encoded enzymes and structural proteins, along with hijacked host cellular factors, that coordinate the multi-step life cycle of the Human Immunodeficiency Virus (HIV) [Patsnap Synapse, 2025; CATIE.ca; PMC, 2023]. This complex system includes three primary enzymes: reverse transcriptase, which converts viral RNA into DNA; integrase, which incorporates viral DNA into the host genome; and protease, which processes viral polyproteins into mature, functional components [Patsnap Synapse, 2025; PMC, 2023; Indole Alkaloids, 2026]. Additionally, structural proteins such as the capsid and envelope glycoproteins (gp120 and gp41) play critical roles in viral entry, uncoating, and assembly [Patsnap Synapse, 2025; CATIE.ca; NIH, 2025]. Antiretroviral therapy (ART) targets these various components to disrupt the viral life cycle and suppress viral replication to undetectable levels [Targets for Inhibition of HIV Replication, 2012; NIH, 2025; PMC, 2023]. By using combinations of drugs like reverse transcriptase inhibitors, integrase inhibitors, and protease inhibitors, clinicians can prevent the progression to AIDS and reduce transmission [Targets for Inhibition of HIV Replication, 2012; NIH, 2025; PMC, 2023]. Despite the success of these treatments, the machinery's high mutation rate leads to drug resistance, and the persistence of the virus in latent reservoirs remains a major barrier to a functional cure [PMC, 2019; Targets for Inhibition of HIV Replication, 2012; PMC, 2023]. Ongoing research continues to explore novel targets within this machinery, such as capsid inhibitors and host-factor modulators, to overcome these challenges [Journal of Medicinal Chemistry, 2015; HIV i-Base, 2025; ResearchGate, 2016].

Other names

HIV-1 replication machineryHIV life cycle machineryHIV viral enzymesHIV replication complex

The mechanism of action involves the targeted inhibition of specific viral components within the replication machinery. Nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs) block the conversion of viral RNA into DNA [Patsnap Synapse, 2025; Targets for Inhibition of HIV Replication, 2012; TAAL+ Healthcare, 2026]. Integrase strand transfer inhibitors (INSTIs) prevent the insertion of viral DNA into the host genome [Patsnap Synapse, 2025; TAAL+ Healthcare, 2026; HIV i-Base, 2025]. Protease inhibitors (PIs) block the cleavage of polyproteins, preventing virion maturation [Patsnap Synapse, 2025; CATIE.ca; PMC, 2023]. Additionally, entry and fusion inhibitors prevent the virus from attaching to or merging with the host cell, while capsid inhibitors disrupt the assembly and disassembly of the viral core [Targets for Inhibition of HIV Replication, 2012; HIV i-Base, 2025].